Table 5.
In vivo antimalaria pharmacodynamic effect of ART in combination with CHR
| Groups | Dosage (mg/kg) | Parasitemia (%, n = 10) | P value | Inhibition (%, n = 10) | |
|---|---|---|---|---|---|
| placebo | ART alone | ||||
| Placebo | 0 | 22.15 ± 6.25 | – | – | |
| CHR-L | 5 | 19.74 ± 13.33 | 0.62 | – | – |
| CHR-M | 10 | 17.19 ± 5.45 | 0.05 | – | – |
| CHR-H | 20 | 18.32 ± 8.86 | 0.25 | – | – |
| ART alone | 5 | 13.95 ± 7.89* | 0.01 | – | 37.06 |
| ART-CHR-L | 5 (1:1) | 9.95 ± 5.36* | 2.73 × 10−5 | 0.07 | 55.10 |
| ART-CHR-M | 10 (1:2) | 8.75 ± 4.25*,# | 2.16 × 10−6 | 0.04 | 60.51# |
| ART-CHR-H | 20 (1:4) | 11.00 ± 4.98* | 2.72 × 10−5 | 0.18 | 50.36 |
* P values of drugs in relation to placebo: P < 0.05
# P values of ART-CHR combination groups in relation to ART alone: P < 0.05